Key insights
- Bruker's European launch of MyGenius PRO, an automated molecular diagnostics system, signals growth in its diagnostics portfolio. Analysts predict a return to profitability for Bruker this year. While the direct impact on US equities is limited, the expansion and positive earnings outlook could contribute to a slightly bullish sentiment for BRKR.
MUNICH - Bruker Corporation (NASDAQ:BRKR) announced the European launch of MyGenius PRO, a fully automated molecular diagnostics system for infectious disease testing, according to a press release statement. The $5.9 billion medical technology company is expanding its diagnostics portfolio as analysts forecast a return to profitability this year with projected earnings of $2.12 per share.
The sample-to-answer system, based on PCR technology, features continuous loading of samples, consumables and reagents with random-access operation. The platform automates the workflow from patient sample to diagnostic result.
At launch, the system’s IVDR menu includes assays for Cytomegalovirus and Epstein-Barr virus from whole blood, and BK virus from urine for testing in immunocompromised patients. Additional assays for HIV-1, Hepatitis B virus, Hepatitis C virus and Human Herpesvirus 6 are planned for release throughout 2026.
Bruker developed the platform through a collaboration with ELITechGroup and Hitachi High Tech Corporation. Hitachi High-Tech will introduce the system in Japan under the tradename LABOSPECT GA-5 with Bruker molecular diagnostic assays compliant with Japanese diagnostic regulations.
The launch expands Bruker’s molecular diagnostics portfolio, which includes the InGenius and BeGenius systems, a CE-IVD assay menu, and LiquidArray assays for syndromic panel testing.
Bruker’s Microbiology & Infection Diagnostics division announced the product at ESCMID Global 2026.
In other recent news, Bruker Corporation has announced the appointment of Thierry Bernard, the current CEO of QIAGEN, to its board of directors. Bernard has been with QIAGEN since 2015 and plans to step down as CEO once a successor is appointed. Meanwhile, Bruker also unveiled new spatial biology platforms at the Advances in Genome Biology and Technology General Meeting. The company is now accepting pre-orders for its PaintScape system, with commercial shipments anticipated in the spring.
In related developments, the U.S. Patent Trial and Appeal Board invalidated key claims of a patent owned by The Brigham and Women’s Hospital, which was exclusively licensed to Seer, Inc. This decision could impact Seer’s operations, given the significance of the invalidated claims. Furthermore, Bruker, along with other spatial genomics companies, experienced a sell-off following a Microsoft announcement about its AI model, GigaTIME. Wolfe Research noted investor concerns about the potential decline in demand for spatial proteomics due to AI advancements.
TD Cowen analyst Dan Brennan commented that the sell-off in spatial genomics stocks might be premature, considering the early-stage development of Microsoft’s AI technology. Bruker continues to focus on expanding its product offerings despite market fluctuations, as evidenced by its recent platform updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.